Literature DB >> 17110813

Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study.

Josep Maria Haro1, Diego Novick, David Suarez, Jordi Alonso, Jean Pierre Lépine, Mark Ratcliffe.   

Abstract

Remission and relapse are clinical outcomes of increasing interest in schizophrenia. We analyzed remission and relapse, and the sociodemographic and clinical factors associated with these outcomes, in the usual care of schizophrenia using the 3-year, follow-up data from a large cohort of outpatients with schizophrenia taking part in the prospective, observational, European Schizophrenia Outpatient Health Outcomes study. Of the 6516 patients analyzed for remission, 4206 (64.6%) achieved remission during the 3-year, follow-up period. Logistic regression analysis revealed that being female, having a good level of social functioning at study entry, and a shorter duration of illness were factors significantly associated with achieving remission. Treatment with olanzapine was also associated with a higher frequency of remission compared with other antipsychotic agents. A Kaplan-Meier survival curve estimated that relapse occurred in approximately 25% of the patients who achieved remission, with the risk of relapse remaining constant during the follow-up period. Shorter duration of illness, having hostile behaviors, and substance abuse were factors associated with a higher risk of relapse, whereas good level of social functioning and the use of olanzapine and clozapine were associated with a lower risk of relapse. In conclusion, the 3-year results of the Schizophrenia Outpatient Health Outcomes study indicate that the likelihood of remission decreases over the longitudinal course of schizophrenia, but risk of relapse is maintained even after 3 years of achieving remission severity levels. Results suggest that treatment with olanzapine is associated with a better chance of achieving remission than other antipsychotics. Moreover, the use of olanzapine and clozapine is associated with a lower risk of relapse compared with risperidone, quetiapine, and typical antipsychotics. The results should be interpreted conservatively because of the observational, nonrandomized study design.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17110813     DOI: 10.1097/01.jcp.0000246215.49271.b8

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  41 in total

Review 1.  Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us?

Authors:  Azizah Attard; David M Taylor
Journal:  CNS Drugs       Date:  2012-06-01       Impact factor: 5.749

2.  Increased use of second generation antipsychotic drugs in primary care: potential relevance for hospitalizations in schizophrenia patients.

Authors:  Macarena C Cáceres; Eva María Peñas-Lledó; Alfredo de la Rubia; Adrián Llerena
Journal:  Eur J Clin Pharmacol       Date:  2007-10-19       Impact factor: 2.953

Review 3.  A tipping point in drug dosing in late-life schizophrenia.

Authors:  Takashi Tsuboi; Takefumi Suzuki; Hiroyuki Uchida
Journal:  Curr Psychiatry Rep       Date:  2011-06       Impact factor: 5.285

4.  Principle standards and problems regarding proof of efficacy in clinical psychopharmacology.

Authors:  Hans-Jürgen Möller; Karl Broich
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-02       Impact factor: 5.270

5.  What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial.

Authors:  Rebecca Schennach; Michael Riedel; Michael Obermeier; Ilja Spellmann; Richard Musil; Markus Jäger; Max Schmauss; Gerd Laux; Herbert Pfeiffer; Dieter Naber; Lutz G Schmidt; Wolfgang Gaebel; Joachim Klosterkötter; Isabella Heuser; Wolfgang Maier; Matthias R Lemke; Eckart Rüther; Stefan Klingberg; Markus Gastpar; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-09-27       Impact factor: 5.270

Review 6.  The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Authors:  Sofia Brissos; Miguel Ruiz Veguilla; David Taylor; Vicent Balanzá-Martinez
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

Review 7.  Conducting clinical research in community mental health settings: Opportunities and challenges.

Authors:  Oleg V Tcheremissine; Whitney E Rossman; Manuel A Castro; Dineen R Gardner
Journal:  World J Psychiatry       Date:  2014-09-22

8.  Cost-Effectiveness of Routine Screening for Autoimmune Encephalitis in Patients With First-Episode Psychosis in the United States.

Authors:  Eric L Ross; Jessica E Becker; Jenny J Linnoila; Djøra I Soeteman
Journal:  J Clin Psychiatry       Date:  2020-11-17       Impact factor: 4.384

9.  Antipsychotic effects of quetiapine in naturalistic long term follow up study.

Authors:  Jung-Sun Lee; Joon Ho Ahn; Do-Hoon Kim; Jong-Jin Kim; Tae-Young Kim; So-Young Yoo; Dong-Geun Lee; Sang-Hyuk Lee; Se-Won Lim; Weon-Jeong Lim; Il-Kyung Jung; Hae-Kyung Jung; Dong-Hwan Cho; In-Hee Cho; Chang-Yoon Kim
Journal:  Psychiatry Investig       Date:  2010-05-04       Impact factor: 2.505

10.  Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States.

Authors:  Nicolas M Furiak; Haya Ascher-Svanum; Robert W Klein; Lee J Smolen; Anthony H Lawson; Robert R Conley; Steven D Culler
Journal:  Cost Eff Resour Alloc       Date:  2009-04-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.